Akebia Therapeutics, Inc.Find Ratings Reports
AKEBIA THERAPEUTICS INC's gross profit margin for the third quarter of its fiscal year 2021 has increased when compared to the same period a year ago. Even though sales decreased, the net income has increased. AKEBIA THERAPEUTICS INC has average liquidity. Currently, the Quick Ratio is 1.38 which shows that technically this company has the ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year, indicating deteriorating cash flow.
At the same time, stockholders' equity ("net worth") has significantly decreased by 56.86% from the same quarter last year. Together, the key liquidity measurements indicate that it is relatively unlikely that the company will face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q3 FY21||Q3 FY20|
|Net Sales ($mil)||48.76||59.99|
|Net Income ($mil)||-59.54||-59.96|
|Balance Sheet||Q3 FY21||Q3 FY20|
|Cash & Equiv. ($mil)||207.2||269.65|
|Total Assets ($mil)||602.27||676.14|
|Total Debt ($mil)||123.21||105.42|
|Profitability||Q3 FY21||Q3 FY20|
|Gross Profit Margin||78.01||73.38|
|Return on Assets||-49.67||-57.81|
|Return on Equity||-218.13||-122.95|
|Debt||Q3 FY21||Q3 FY20|
|Share Data||Q3 FY21||Q3 FY20|
|Shares outstanding (mil)||174.55||143.33|
|Div / share||0.0||0.0|
|Book value / share||0.79||2.22|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||2048552.0||3732029.0|
SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. To use another comparison, its price-to-book ratio of 3.40 indicates a discount versus the S&P 500 average of 4.61 and a significant discount versus the subsector average of 10.93. The price-to-sales ratio is well below both the S&P 500 average and the subsector average, indicating a discount. After reviewing these and other key valuation criteria, AKEBIA THERAPEUTICS INC proves to trade at a discount to investment alternatives.
|AKBA NM||Peers 34.44||AKBA NM||Peers 21.61|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
AKBA's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
AKBA's P/CF is negative making the measure meaningless.
|AKBA NM||Peers 18.67||AKBA NA||Peers 1.11|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
AKBA's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|AKBA 3.40||Peers 10.93||AKBA 35.82||Peers 70.19|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
AKBA is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, AKBA is expected to significantly trail its peers on the basis of its earnings growth rate.
|AKBA 2.21||Peers 79.55||AKBA -31.64||Peers 542.99|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
AKBA is trading at a significant discount to its subsector on this measurement.
Lower. A sales growth rate that trails the subsector implies that a company is losing market share.
AKBA significantly trails its peers on the basis of sales growth.